Soliris Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Soliris market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to factors such as regulatory approvals, heightened awareness of rare diseases, rising demand for complement inhibition, expanded indications, and increased diagnosis rates.

In the forecast period, growth is driven by the rising prevalence of complement-mediated diseases, advancements in gene therapy, expanded market access in emerging regions, growth in biosimilars, and better patient compliance. Key trends in the forecast period include the adoption of combination therapies, a shift towards patient-centric treatments, the move towards personalized medicine, the growing use of digital health technologies, and an emphasis on cost-effectiveness and value-based care.

The increasing prevalence of rare blood disorders is expected to propel the growth of the soliris market. Rare blood disorders, such as hemophilia, sickle cell anemia, and thalassemia, are conditions that affect blood production, components, or clotting. The rise in these disorders is attributed to improved diagnostic techniques, greater awareness, and genetic and environmental factors. Soliris (eculizumab) helps manage these conditions by inhibiting the complement protein C5, which prevents excessive complement activation, reducing the risk of severe complications like hemolysis and organ damage. According to NHS England, approximately 17,000 people are living with sickle cell disease, with 250 new cases diagnosed annually. This increasing prevalence is driving the demand for soliris.

The growing investment in rare disease research is fueling the soliris market. With advancements in genomics and the recognition of unmet medical needs, there is increased investment in rare disease research, which helps expand the understanding of conditions treated by Soliris. This leads to a rise in demand for effective treatments. For instance, in July 2023, the UK government invested significant funds, including USD 834.2 million for Biomedical Research Centers and USD 15.06 million for the UK Rare Disease Research Platform. This investment aims to enhance diagnostic and treatment development for rare diseases, further promoting the growth of the Soliris market.

A key trend in the soliris market is the development of biologic medicines for treating neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that affects the central nervous system. This development improves treatment options for rare blood disorders. In October 2023, AstraZeneca received approval for Soliris from China's National Medical Products Administration (NMPA) for the treatment of adult NMOSD patients who are positive for anti-aquaporin-4 (AQP4) antibodies. Soliris is the first and only complement inhibitor approved for NMOSD treatment in China, marking a significant advancement in managing this debilitating condition.

The key players operating in the soliris market is Pfizer.

North America was the largest region in the Soliris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in soliris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the soliris market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Soliris (eculizumab) is a monoclonal antibody developed by Alexion Pharmaceuticals. It works by inhibiting the complement protein C5, thereby reducing inflammation and damage caused by an overactive immune system. Soliris is primarily used to treat rare diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG).

The main types of soliris are plasma exchange and plasma infusion. Plasma exchange is a medical procedure in which a patient's plasma is removed and replaced to treat various conditions, including autoimmune or blood disorders. It is used for treating conditions like paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The soliris market research report is one of a series of new reports that provides soliris market statistics, including the soliris industry's global market size, regional shares, competitors with a soliris market share, detailed Soliris market segments, market trends and opportunities, and any further data you may need to thrive in the soliris industry. This soliris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The soliris market consists of sales of soliris (eculizumab) 300 mg/30 mL vial, soliris (eculizumab) injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.